Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.

Anorexia Clinical Trial

Official title:

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients: A Randomized, Double-Blind Trail.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05380479
• Other study ID #: BSMMU/2022/4193
• Status: Recruiting
• Phase: Phase 2
• Start date: June 1, 2022
• Est. completion date: February 1, 2023

Study information

• Verified date: May 2022
• Source: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
• Contact: Iftekhar Chowdhury, MD
• Phone: +8801816197635
• Email: ichowdhury42[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was 8 weeks randomized, double-blind trail to assess the effect of mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients in 80 patients. Participants were assessed at baseline, 4 weeks and 8 weeks. Subject were randomized to receive either mirtazapine 15 mg tablet daily or megestrol acetate 160 mg tablet daily for 8 weeks. The primary outcome was the measure of FAACT(A/C) score and the secondary measure includes weight, BMI, quality of life and evaluate adverse effects.

Description:

Cancer-related cachexia and anorexia (CRCA) comprises one of the most common syndrome of advanced cancers characterize by anorexia, tissue wasting and loss of body weight accompanied by a decrease in muscle mass and adipose tissue and by poor performance status that often precedes death . Death usually occurs when there is a 30% weight loss. The prevalence of CRCA increases from 50 to 80% before death, and in more than 20% of cancer patients, it is the cause of death. Cancer-related cachexia and anorexia (CRCA) is associated not only with impaired quality of life in patients and family members but also with shorter survival. The management of cancer-related cachexia and anorexia (CRCA) is a great challenge in clinical practice. To date, practice guidelines for the prevention and treatment of CRCA are lacking. Although megestrol acetate and dexamethasone have shown benefits for CRCA in terms of weight gain. There is no definitive evidence that these agents improve patient quality of life. This proposed study is therefore an effort whether there is any role of mirtazapine to improvement of anorexia in cancer patients. This study will be a randomized, double-blind, clinical trial. It will be conducted in the department of pharmacology, BSMMU in collaboration with the department of clinical oncology, BSMMU, NIRCH & Delta Hospital from the day of approval by the IRB to June, 2022. A total of eighty (80) patients attend in the outpatient department of clinical oncology, BSMMU, NIRCH & Delta Hospital diagnosed as cancer anorexia will be selected for the study according to inclusion and exclusion criteria. Then participants will randomly be assigned into two intervention groups. The cancer anorexia of each participant will be assessed by Functional Assessment of Anorexia/Cachexia Therapy at baseline. The group A (40) will receive mirtazapine15mg tablet and other group B (40) will receive megestrol acetate160mg tablet orally once a day for 8 weeks. After 4 and 8 weeks each participant will be assessed once again by Functional Assessment of Anorexia/Cachexia Therapy. The quality of life of CRAC each participant will be assessed by EORTC QLQ-C30.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: February 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients aged = 18 years, with a histologically diagnosed advanced-stage tumor at any site.

• Assumptive or documented loss of >5% of pre-illness or ideal body weight (body mass index) in the previous 3 months.

• Patients could be receiving concomitant chemotherapy, radiotherapy and/or palliative supportive care.

• Patients ECOG Performance Status 0-3.

Exclusion Criteria:

• Patients with a mechanical obstruction to feeding.

• Patients with high doses of corticosteroids.

• Patients with clinically bulky ascites and generalized edema.

• Patients with inability to take oral medications.

• History of uncontrolled diabetes mellitus and hypertension.

Related Conditions & MeSH terms

• Anorexia
• Cachexia

Intervention

Drug:
• Mirtazapine
mirtazaine15 mg tablet daily for 8 weeks.
• Megestrol Acetate
megestrol acetate 160 mg tablet daily for 8 weeks.

Locations

Country	Name	City	State
Bangladesh	Bangabandhu Sheikh Mujib Medical University	Dhaka

Sponsors (1)

Lead Sponsor	Collaborator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with Anorexia	The primary endpoint will assess the percentage of patients who continue to present anorexia after 8 weeks of treatment.; Anorexia will be defined as the lack of desire to eat, lack of appetite, as measured using the validated version of the Anorexia / Cachexia Scale from the Functional Assessment of Anorexia Cachexia Therapy (FAACT). A score of less than or equal to 24 will be considered diagnostic for anorexia	From the baseline assessment to 8 weeks]
Secondary	Weight	Sum of all the components of the organism and represents the total body mass.	From the baseline assessment to 8 weeks]
Secondary	Body Mass Index	It is an index of the weight of a person in relation to his height BMI = Weight (Kg.) / [height (m) * height) (m)]	From the baseline assessment to 8 weeks]
Secondary	Quality of life - physical functioning	The physical functioning will be evaluated using the validated Bangla version of the European Organization for the Research and Treatment of Cancer (EORTC) Quality of life questionnaires specific for cancer using the physical functioning scale (from QLQ-C30 version 3.0).The Change over time as well as the difference between groups will be analyzed.	From the baseline assessment to 8 weeks]
Secondary	Incidence of treatment-related Adverse Events [Time Frame: 8 weeks]	The questioning about the occurrence of treatment-related adverse events will also be performed at the outpatient clinic at baseline and weeks 4 and 8 during the follow-up.	Time Frame: 8 weeks